Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 10, 2026, 2:23 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 1,104 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Influenza Vaccines Clear all
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Study of Fluzone® Quadrivalent, Fluzone® Intradermal, and Fluzone® High-Dose, Influenza Vaccines in Adults

NCT02258334
View directory record Official record
Conditions
Influenza
Interventions
Fluzone® Quadrivalent vaccine, 2014-2015 formulation, Fluzone I®ntradermal vaccine, 2014-2015 formulation, Fluzone High Dose vaccine, 2014-2015 formulation
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
18 Years and older
Enrollment
208 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
4
States / cities
Santa Rosa, California • Council Bluffs, Iowa • Metairie, Louisiana + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 18, 2015 · Synced Sep 10, 2026, 2:23 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Duration of Immune Response to Influenza Vaccination in Patients With RA

NCT02311855
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Influenza vaccine
Biological
Lead sponsor
Bassett Healthcare
Other
Eligibility
40 Years to 75 Years
Enrollment
87 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
1
States / cities
Cooperstown, New York
Source: ClinicalTrials.gov public record
Updated Jan 5, 2017 · Synced Sep 10, 2026, 2:23 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety of Lactobacillus Rhamnosus GG Versus Placebo in Elderly Subjects Receiving Live Attenuated Influenza Vaccine

NCT01545349
View directory record Official record
Conditions
Healthy, Influenza
Interventions
Lactobacillus rhamnosus GG ATCC 53103 (LGG), Placebo, Live attenuated influenza vaccine
Biological
Lead sponsor
Patricia L. Hibberd
Other
Eligibility
65 Years to 80 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 10, 2017 · Synced Sep 10, 2026, 2:23 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Evaluate Safety & Immunogenicity of GSK Bio's Influenza Vaccine GSK576389A After Repeated Vaccination in Elderly Adults

NCT00529516
View directory record Official record
Conditions
Influenza
Interventions
Fluarix, GSK Biologicals Influenza Vaccine GSK576389A
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
1,252 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
9
States / cities
Clearwater, Florida • Coral Gables, Florida • Milford, Massachusetts + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 7, 2018 · Synced Sep 10, 2026, 2:23 PM EDT
Completed No phase listed Observational Accepts healthy volunteers Results available

Flublok v. Standard Dose Vaccine Effectiveness Among Kaiser Permanente Northern California Adults 18-64 Years

NCT03694392
View directory record Official record
Conditions
Influenza, Pneumonia, Lower Respiratory Tract Infection, Acute Myocardial Infarction, Congestive Heart Failure, Stroke
Interventions
Flublok Quadrivalent, Standard Dose Inactivated Influenza Vaccine (SD-IIV)
Biological
Lead sponsor
Kaiser Permanente
Other
Eligibility
18 Years to 64 Years
Enrollment
2,776,278 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2022
U.S. locations
1
States / cities
Oakland, California
Source: ClinicalTrials.gov public record
Updated Apr 7, 2025 · Synced Sep 10, 2026, 2:23 PM EDT
Completed Phase 3 Interventional

Phase 3 Efficacy and Safety Study of Favipiravir for Treatment of Uncomplicated Influenza in Adults

NCT02008344
View directory record Official record
Conditions
Influenza
Interventions
favipiravir, placebo
Drug
Lead sponsor
MDVI, LLC
Industry
Eligibility
18 Years to 80 Years
Enrollment
1,161 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
147
States / cities
Birmingham, Alabama • Huntsville, Alabama • Camp Verde, Arizona + 123 more
Source: ClinicalTrials.gov public record
Updated Nov 10, 2015 · Synced Sep 10, 2026, 2:23 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

St. Jude Open Label H5 Trial

NCT00311675
View directory record Official record
Conditions
Influenza
Interventions
Inactivated Influenza A/H5N1 Vaccine (sanofi pasteur)
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 26, 2010 · Synced Sep 10, 2026, 2:23 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

Safety, Tolerability and Immunogenicity of a Plant-made Seasonal Quadrivalent VLP Influenza Vaccine in Adults

NCT01991587
View directory record Official record
Conditions
Virus Diseases, RNA Virus Infections, Respiratory Tract Diseases, Respiratory Tract Infections
Interventions
Low dose of quadrivalent VLP vaccine, Medium dose of quadrivalent VLP vaccine, High dose of quadrivalent VLP vaccine, Placebo
Biological
Lead sponsor
Medicago
Industry
Eligibility
18 Years to 49 Years
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jun 10, 2020 · Synced Sep 10, 2026, 2:23 PM EDT
Recruiting Early Phase 1 Interventional

A Phase 0 Window of Opportunity Trial of Intratumoral Seasonal Influenza Immunization in Cutaneous Squamous Cell Carcinoma (CSCC) Patients Awaiting Curative Excision

NCT06664151
View directory record Official record
Conditions
Skin Cancer, Cutaneous Squamous Cell Carcinoma (CSCC), Cutaneous Squamous Cell Cancer
Interventions
Fluzone Trivalent
Biological
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 1, 2025 · Synced Sep 10, 2026, 2:23 PM EDT
Completed Not applicable Interventional

Effectiveness of Influenza Vaccine Reminder Systems

NCT01852656
View directory record Official record
Conditions
Asthma, Chronic Obstructive Pulmonary Disease
Interventions
Postcard and IVR Reminder Group, Postcard Only Reminder Group, IVR Only Reminder Group
Behavioral
Lead sponsor
Kaiser Permanente
Other
Eligibility
19 Years to 64 Years
Enrollment
12,255 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated May 13, 2013 · Synced Sep 10, 2026, 2:23 PM EDT
Not listed Phase 3 Interventional Accepts healthy volunteers

Study of the Protective Effect of an Injectable Influenza Vaccine Against Influenza Illness in Adults Under 50 y.o.

NCT00216242
View directory record Official record
Conditions
Influenza
Interventions
Influenza virus vaccine (Fluviral), Saline placebo
Biological
Lead sponsor
ID Biomedical Corporation, Quebec
Industry
Eligibility
18 Years to 49 Years
Enrollment
7,400 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2007
U.S. locations
43
States / cities
Sacramento, California • San Francisco, California • Denver, Colorado + 34 more
Source: ClinicalTrials.gov public record
Updated Dec 10, 2006 · Synced Sep 10, 2026, 2:23 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Safety and Immunogenicity of Different Dosages of High-Dose Quadrivalent Influenza Vaccine in Children 6 Months to 17 Years of Age

NCT03698279
View directory record Official record
Conditions
Influenza
Interventions
High-Dose Quadrivalent Influenza Vaccine (QIV-HD) 30 μg (split-virion, inactivated), High-Dose Quadrivalent Influenza Vaccine (QIV-HD) 45 μg, (split-virion, inactivated), High-Dose Quadrivalent Influenza Vaccine (QIV-HD) 60 µg (split-virion, inactivated), Fluarix Quadrivalent Influenza vaccine (Unadjuvanted QIV-SD) (Inactivated), FLUAD Pediatric (adjuvanted TIV) (Surface Antigen, Inactivated)
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
6 Months to 17 Years
Enrollment
665 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
13
States / cities
San Diego, California • Miami, Florida • Atlanta, Georgia + 8 more
Source: ClinicalTrials.gov public record
Updated Apr 3, 2022 · Synced Sep 10, 2026, 2:23 PM EDT
Terminated Phase 3 Interventional Results available

Intramuscular Peramivir in Subjects With Uncomplicated Acute Influenza

NCT00610935
View directory record Official record
Conditions
Influenza
Interventions
Peramivir, Placebo
Drug
Lead sponsor
BioCryst Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
96
States / cities
Millbrook, Alabama • Tuscaloosa, Alabama • Phoenix, Arizona + 80 more
Source: ClinicalTrials.gov public record
Updated Mar 16, 2021 · Synced Sep 10, 2026, 2:23 PM EDT
Completed Phase 2 Interventional

Influenza Vaccination in Patients Receiving Antineoplastic Therapy for Non-Hodgkin's Lymphoma

NCT00307710
View directory record Official record
Conditions
Lymphoma
Interventions
Trivalent Baculovirus-expressed Influenza HA vaccine
Biological
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 30, 2012 · Synced Sep 10, 2026, 2:23 PM EDT
Not yet recruiting Phase 4 Interventional Accepts healthy volunteers

How Healthy Adults Respond to the Nasal Flu Vaccine

NCT07726862
View directory record Official record
Conditions
Mucosal Immune Response to Influenza Vaccination
Interventions
FluMist (Live Attenuated Influenza Vaccine)
Biological
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2031
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Jul 23, 2026 · Synced Sep 10, 2026, 2:23 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ≥50 Years of Age

NCT06602024
View directory record Official record
Conditions
Seasonal Influenza
Interventions
mRNA-1010, Fluarix®, Influsplit® Tetra, Fluarix Tetra, Alpharix® Tetra
Biological
Lead sponsor
ModernaTX, Inc.
Industry
Eligibility
50 Years and older
Enrollment
40,817 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
188
States / cities
Anniston, Alabama • Athens, Alabama • Birmingham, Alabama + 150 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2025 · Synced Sep 10, 2026, 2:23 PM EDT
Withdrawn Phase 1 Interventional

A Study of the Pharmacology of Oseltamivir (Tamiflu) in Pregnancy

NCT00873886
View directory record Official record
Conditions
Pregnancy, Influenza
Interventions
Oseltamivir (Tamiflu), Blood Draws
Drug · Procedure
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 28, 2015 · Synced Sep 10, 2026, 2:23 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Influenza Vaccination in the Emergency Department

NCT00822627
View directory record Official record
Conditions
Influenza
Interventions
Influenza Vaccination, Education and referral
Drug · Behavioral
Lead sponsor
University of Arizona
Other
Eligibility
6 Months and older
Enrollment
140 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Jan 13, 2009 · Synced Sep 10, 2026, 2:23 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

A Study Evaluating the Safety and Tolerability of a Seasonal Influenza Vaccine Containing LIQ001

NCT01224262
View directory record Official record
Conditions
Influenza
Interventions
Fluzone® (2010/2011 Inactivated Trivalent Influenza Vaccine), LIQ001 (0.45mg), LIQ001 (1.8mg)
Biological
Lead sponsor
Liquidia Technologies, Inc.
Industry
Eligibility
18 Years and older
Enrollment
152 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Melbourne, Florida
Source: ClinicalTrials.gov public record
Updated Feb 28, 2013 · Synced Sep 10, 2026, 2:23 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Post-Marketing Observational Study of Safety Following Vaccination With Flublok® Compared to Licensed IIV in Adults

NCT02600585
View directory record Official record
Conditions
Human Influenza
Interventions
Recombinant Influenza Vaccine, Inactivated Influenza Vaccine
Biological
Lead sponsor
Protein Sciences Corporation
Industry
Eligibility
18 Years and older
Enrollment
254,648 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Oakland, California
Source: ClinicalTrials.gov public record
Updated Oct 11, 2017 · Synced Sep 10, 2026, 2:23 PM EDT
Withdrawn Phase 2 Interventional

Assessment of Efficacy of CR8020 and CR6261, Monoclonal Antibodies, Against Influenza Infection

NCT01992276
View directory record Official record
Conditions
Influenza
Interventions
CR8020, CR6261, Placebo
Biological
Lead sponsor
Crucell Holland BV
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
21
States / cities
Fresno, California • Stanford, California • Washington D.C., District of Columbia + 18 more
Source: ClinicalTrials.gov public record
Updated Mar 3, 2014 · Synced Sep 10, 2026, 2:23 PM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of an H1N1 Influenza Vaccine in People With Asthma

NCT00978120
View directory record Official record
Conditions
H1N1 Influenza Virus
Interventions
H1N1 vaccine high dose, H1N1 vaccine low dose
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
12 Years and older
Enrollment
390 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
7
States / cities
Atlanta, Georgia • St Louis, Missouri • Winston-Salem, North Carolina + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 9, 2012 · Synced Sep 10, 2026, 2:23 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Resistance Exercise to Improve Flu Vaccine for Older Adults

NCT03736759
View directory record Official record
Conditions
Influenza, Human
Interventions
Exercise
Behavioral
Lead sponsor
University of Houston
Other
Eligibility
65 Years and older
Enrollment
29 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2021
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 16, 2022 · Synced Sep 10, 2026, 2:23 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Evaluation of the Safety and Immunogenicity of a Recombinant Trivalent Nanoparticle Influenza Vaccine With Matrix M-1 Adjuvant (NanoFlu)

NCT03293498
View directory record Official record
Conditions
Influenza
Interventions
NanoFlu, Fluzone HD - Day 0, Fluzone HD - Day 21, Saline - Day 21
Biological · Other
Lead sponsor
Novavax
Industry
Eligibility
60 Years and older
Enrollment
330 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
3
States / cities
Raleigh, North Carolina • Rocky Mount, North Carolina • Statesville, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 20, 2022 · Synced Sep 10, 2026, 2:23 PM EDT